Co-Diagnostics price to sales ratio CODX

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 4.7×
7-year median: 4.5×
Against its 7-year history: 53rd; percentile: 0 is its lowest day, 100 its highest
7-year range: 1.2× to 198×
Peer median: 1.4×

Co-Diagnostics' price to sales ratio is 4.7× as of Oct 23, 2026.

That is above its 7-year median of 4.5×, close to the middle of its last 7 years.

Over that time it ranged from 1.2× in Apr 2023 to 198× in Oct 2019.

The median for 10 healthcare stocks of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	4.7×	4.7×	42.8×
2025	28.2×	2.0×	45.0×
2024	3.2×	3.2×	9.2×
2023	8.7×	1.2×	9.1×
2022	1.5×	1.3×	2.6×
2021	2.5×	2.3×	10.1×
2020	5.5×	5.5×	174×
2019	137×	131×	198×

Against its peers

Companies in Healthcare nearest Co-Diagnostics' size, closest first, today.

Company	Price to sales ratio
CODXCo-Diagnostics	4.7×
OXBROXBRIDGE RE HOLDINGS	2.8×
EDUCEducational Development	0.4×
GTIMGood Times Restaurants	0.1×
MDRRMedalist Diversified	1.6×
BCGBinah Capital	0.1×
VIPVulcan Infrastructure & Power	0.4×
MXCMexco Energy	3.0×
CKXCKX Lands	31.0×
MSGMMotorsport Games	1.5×
ATCHAtlasClear	1.2×
Peer median	1.4×

Where Co-Diagnostics ranks

#85of 116Medical instruments and supplies stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Co-Diagnostics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.